Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 181

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 181
---
| Revenues                 |     | $ | —          |   |
| Net loss                 |     | $ | (1,243,144 | ) |

Consolidated unaudited pro forma information:

The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the twelve-month
period ended June 30, 2024. These amounts have been estimated after applying the Company’s accounting policies:

| Schedule of consolidated 
 proforma information     |     |   |             |   |
|:-------------------------|:----|:--|:------------|:--|
| Revenues                 |     | $ | —           |   |
| Net                      
 loss                     |     | $ | (83,571,822 | ) |

The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month
period ended June 30, 2023. These amounts have been estimated after applying the Company’s accounting policies:

| Revenues |     | $ | —           |   |
| Net loss |     | $ | (42,490,305 | ) |

F-39

NOTE 14 — SEGMENT REPORTING

Beginning with the year ended June 30, 2024, the Company has two reportable segments.
Prior to the year ended June 30, 2024, the Company had only a single reportable segment, the acquisition and integration of Renovaro Cube
resulted in the identification of a separate reportable segment by the Company's chief operating decision maker. These segments have different
strategic and economic goals and are managed separately because they require different technology and marketing strategies.

| Reportable 
 Segment    |     | Description                                                                                                           |
| RENB       |     | Developing                                                                                                            
 new immunotherapies to combat cancer                                                                                  |
| RENC       |     | Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection |

The Company’s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2024, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of